Pay in 4 interest-free payments of $5.09 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Biochem Biophys Res Commun 499(3):499505
The SURMOUNT-OSA trial demonstrated: Mean AHI reduction of approximately 25 to 30 events per hour at 15 mg tirzepatide Significant percentage of patients moving from severe to mild OSA classification Effects observed in both CPAP-using and non-CPAP-using populations Concurrent weight loss consistent with SURMOUNT-1 outcomes Coverage under the OSA pathway has expanded steadily through 2025 and into 2026 across OptumRx-administered plans
Hypothalamic CaMKK2 contributes to the regulation of energy balance
Triglycerides drop the most
US$ 27.19
US$ 26.57
US$ 23.40
